An FDA advisory committee voted against recommending a psychedelic treatment for PTSD, citing insufficient data for what many described as a still-promising path forward.The Psychopharmacologic Drugs Advisory Committee met June 4 to discuss a new drug application for midomafetamine (MDMA) — submitted by Lykos Therapeutics, formerly MAPS Public Benefit Corporation. It was the first FDA